Novel micro-RNA therapeutic hits early targets in ischemic heart diseases
Earlier this year, Horizon announced a new collaboration and license agreement with Mammoth Biosciences.
Read MoreEarlier this year, Horizon announced a new collaboration and license agreement with Mammoth Biosciences.
Read MoreEli Lilly recently announced plans to postpone most new COVID-19-unrelated study starts.
Read MoreSense Biodetection has also pitched in, announcing an accelerated programme to launch the world’s first instrument-free, point-of-care molecular diagnostic test for the novel virus.
Read MoreThe approval was based on the Phase III CASPIAN trial, in which the risk of death was reduced by 27%.
Read MoreThe European authorisation is based on the Phase III ARAMIS trial.
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479